NCT06578676View on ClinicalTrials.gov

To Evaluate the Safety and Pharmacokinetic Interaction Between HODO-22251 and HODO-22252 in Healthy Adults

PHASE1RecruitingINTERVENTIONAL
Enrollment

56

Participants

Timeline

Start Date

June 20, 2024

Primary Completion Date

September 2, 2024

Study Completion Date

November 30, 2024

Conditions
Type 2 DiabetesDyslipidemias
Interventions
DRUG

Empagliflozin 25 MG

PO, QD

DRUG

Ezetimibe/Rosuvastatin 10/10mg

PO, QD

DRUG

Empagliflozin 25 MG with Ezetimibe/Rosuvastatin 10/10mg

PO, QD

Trial Locations (1)

Unknown

RECRUITING

Kyungpook national university hospital, Daegu

Sponsors

Lead Sponsor

Hyundai Pharm
All Listed Sponsors
collaborator

Kyungpook National University Hospital

OTHER

lead

Hyundai Pharm

INDUSTRY